Investors / United States / EcoR1 Capital
EcoR1 Capital
Venture capital · San Francisco, CA, United States · North America
EcoR1 Capital is a biotech-focused investment fund that invests in therapeutic companies developing new medicines for untreated diseases. It describes itself as building long-term partnerships with entrepreneurs and evaluating companies on management, science and financing strategy.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticslife sciencesdrug discoveryhealthcare
Your fit with EcoR1 Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsEcoR1 Capital lists 19 checked portfolio companies on its own site and is named in 5 funding rounds. Its most frequent entry is Growth, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 93% of its companies are based in United States. It invests most often alongside RA Capital, Droia Ventures and Foresite Capital.
Counts come from funding rounds that name EcoR1 Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not EcoR1 Capital's whole history. Rounds on record name 5 companies; its own site lists 19. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundEcoR1 Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 25% |
| Series B | 25% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 1 | 0 |
| '26 | 3 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 49th | 19 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 64th | 5% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 4 |
| Droia Ventures | 3 |
| Foresite Capital | 3 |
| Frazier Life Sciences | 3 |
| ARK Venture Fund | 2 |
| Atlas Venture | 2 |
| Canaan | 2 |
| Casdin Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1789%
- No longer answers00%
- Points to another company211%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare EcoR1 Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with EcoR1 Capital| Date | Company | Stage |
|---|---|---|
| 30 Oct 2026 | Series A | |
| 13 Feb 2026 | Round | |
| 8 Jan 2026 | Series B | |
| 15 Apr 2025 | Series C+ |
Round details for EcoR1 Capital
Amounts, full round histories and every co-investor in EcoR1 Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
19 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Accent Therapeutics develops small molecule therapeutics for patients living with cancer | Healthcare & Biotech | Portfolio page | ||
| Actio Biosciences is involved in clinical trials for therapies, including for KCNT1-Related Epilepsy. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Portfolio page | ||||
Healthcare & Biotech | Portfolio page | |||
| Anagin is developing novel targeted therapies for addressing pathologies associated with disrupted synaptic plasticity in the central nervous system leading to psychiatric diseases. | Healthcare & Biotech | Portfolio page | ||
| Attovia Therapeutics is developing next-generation biotherapeutics for immune-mediated diseases. | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| BridgeBio develops medicines for genetic conditions | Healthcare & Biotech | Portfolio page | ||
| Cellares manufactures cell therapies and provides related services and technologies | Healthcare & Biotech | Portfolio page | ||
| Centessa Pharmaceuticals develops and pursues medicines for patients with various disorders, including sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders. | Healthcare & Biotech | Portfolio page | ||
| Diagonal Therapeutics develops clustering antibodies to correct the root cause of genetic diseases | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Eikon Therapeutics is a company with offices in multiple locations. | Healthcare & Biotech | Portfolio page | ||
| Epikast partners with biopharma and healthcare organizations to engage their stakeholders, including patients, physicians, and other healthcare providers, by providing medically trained talent and AI-driven engagement tools. | Healthcare & Biotech | Portfolio page | ||
| Freenome develops blood-based screening tests to detect cancer at its earliest stages | Healthcare & Biotech | Portfolio page | ||
| Immunic Therapeutics is a biotechnology company that develops oral therapies for neurologic and autoimmune diseases. | Healthcare & Biotech | Feb 2026Round | Funding round | |
| Neurogene develops life-changing genetic medicines for people and their families impacted by devastating neurological diseases. | Healthcare & Biotech | Portfolio page | ||
| Omniox is developing breakthrough H-NOX platform technology into oxygen delivery vehicles to treat significant unmet medical needs | Healthcare & Biotech | Portfolio page | ||
| Setara Biosciences develops small-molecule precision medicines that target the underlying causes of disease | Healthcare & Biotech | Oct 2026Series A | Funding round |
About this data
site last read 5 Nov 2026- Site
- ecor1cap.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 13 May 2024
- Companies checked
- 19
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get EcoR1 Capital's profile as data
Pull EcoR1 Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/ecor1cap.com
# also
GET /v1/firms/ecor1cap.com/portfolio
GET /v1/firms/ecor1cap.com/coinvestors
GET /v1/firms/ecor1cap.com/news